About
Mohini Ranganathan is an Associate Professor of Psychiatry at Yale University School of Medicine, with affiliations in the MR Core Neuroscience Research Training Program and the Schizophrenia Research Clinic. She holds roles in multiple research initiatives, including the Yale Center for the Science of Cannabis and Cannabinoids and Yale Ventures. Her work focuses on cannabis neurobiology, schizophrenia, and the effects of ketamine and cannabinoids on mental health. Ranganathan earned her MBBS from Calicut Medical College in 1999.
Research Interests:
- Cannabinoid receptor dynamics in addiction and mental health
- Pharmacological mechanisms of ketamine in depression
- Schizophrenia neurobiology and synaptic dysfunction
- Gender differences in drug responses
- Clinical trials for opioid use disorder and cannabis dependence
Awards:
- Exemplary Psychiatrist Award (2022), National Alliance on Mental Illness (NAMI)
- Blavatnik Fund for Innovation Award (2024)
Grants & Trials:
- Principal Investigator for the Schizophrenia Spectrum Biomarkers Consortium (SSBC)
- Sub-investigator in studies on cannabis neurodevelopment and sleep-dependent learning in psychosis
Labs & Teams: Leads the Ranganathan Research Lab, focusing on translational neuroscience and clinical pharmacology.
0Publications listed
